AIMS: Recent data indicate that right ventricular systolic dysfunction (RVSD) by cardiac magnetic resonance imaging (CMR) is a strong predictor of outcome in heart failure. However, the prognostic significance of RVSD by CMR in heart failure with preserved ejection fraction (HFpEF) is unknown. METHODS AND RESULTS: We prospectively enrolled 171 HFpEF patients who underwent CMR in addition to invasive and non-invasive testing. RVSD, defined as right ventricular (RV) EF <45% by CMR, was present in 33 (19.3 %) patients. Patients were followed for 573 ± 387 days, during which 41 had a cardiac event. Patients with RVSD presented with more frequent history of AF (P = 0.038), significantly higher resting heart rate (P = 0.009), shorter 6-min walk distance (P = 0.036), and higher NT-pro BNP serum levels (P < 0.001), and were more symptomatic (P < 0.001). With respect to haemodynamic parameters, RVSD was associated with respect to haemodynamic parameters, RVSD was associated with higher diastolic pulmonary artery pressure (P = 0.045), with higher pulmonary vascular resistance (P = 0.048), higher transpulmonary gradient (P = 0.042), and higher diastolic pulmonary vascular pressure gradient (P = 0.007). In the multivariable Cox analysis, RVSD (P < 0.001) remained significantly associated with cardiac events, in addition to diabetes (P = 0.011), 6-min walk distance (P = 0.018), and systolic pulmonary artery pressure (P = 0.003). CONCLUSIONS: Although HFpEF is considered a disease of the left ventricle, respective imaging parameters are not related to outcome. In contrast, RVSD by CMR is independently associated with mortality and clinical status in these patients, and provides a useful tool for risk stratification.
AIMS: Recent data indicate that right ventricular systolic dysfunction (RVSD) by cardiac magnetic resonance imaging (CMR) is a strong predictor of outcome in heart failure. However, the prognostic significance of RVSD by CMR in heart failure with preserved ejection fraction (HFpEF) is unknown. METHODS AND RESULTS: We prospectively enrolled 171 HFpEF patients who underwent CMR in addition to invasive and non-invasive testing. RVSD, defined as right ventricular (RV) EF <45% by CMR, was present in 33 (19.3 %) patients. Patients were followed for 573 ± 387 days, during which 41 had a cardiac event. Patients with RVSD presented with more frequent history of AF (P = 0.038), significantly higher resting heart rate (P = 0.009), shorter 6-min walk distance (P = 0.036), and higher NT-pro BNP serum levels (P < 0.001), and were more symptomatic (P < 0.001). With respect to haemodynamic parameters, RVSD was associated with respect to haemodynamic parameters, RVSD was associated with higher diastolic pulmonary artery pressure (P = 0.045), with higher pulmonary vascular resistance (P = 0.048), higher transpulmonary gradient (P = 0.042), and higher diastolic pulmonary vascular pressure gradient (P = 0.007). In the multivariable Cox analysis, RVSD (P < 0.001) remained significantly associated with cardiac events, in addition to diabetes (P = 0.011), 6-min walk distance (P = 0.018), and systolic pulmonary artery pressure (P = 0.003). CONCLUSIONS: Although HFpEF is considered a disease of the left ventricle, respective imaging parameters are not related to outcome. In contrast, RVSD by CMR is independently associated with mortality and clinical status in these patients, and provides a useful tool for risk stratification.
Authors: Pankaj Garg; Hosamadin Assadi; Rachel Jones; Wei Bin Chan; Peter Metherall; Richard Thomas; Rob van der Geest; Andrew J Swift; Abdallah Al-Mohammad Journal: Sci Rep Date: 2021-01-12 Impact factor: 4.379
Authors: Maximilian von Roeder; Johannes Tammo Kowallick; Karl-Philipp Rommel; Stephan Blazek; Christian Besler; Karl Fengler; Joachim Lotz; Gerd Hasenfuß; Christian Lücke; Matthias Gutberlet; Holger Thiele; Andreas Schuster; Philipp Lurz Journal: Clin Res Cardiol Date: 2019-05-03 Impact factor: 5.460
Authors: Benedikt Koell; Caroline Zotter-Tufaro; Franz Duca; Andreas A Kammerlander; Stefan Aschauer; Daniel Dalos; Marlies Antlanger; Manfred Hecking; Marcus Säemann; Julia Mascherbauer; Diana Bonderman Journal: Int J Cardiol Date: 2016-12-21 Impact factor: 4.164
Authors: Stefan Aschauer; Caroline Zotter-Tufaro; Franz Duca; Andreas Kammerlander; Daniel Dalos; Julia Mascherbauer; Diana Bonderman Journal: Int J Cardiol Date: 2016-11-18 Impact factor: 4.164